COVID-19 Outcome Prediction Algorithm
COPA
Multi-Dimensional Outcome Prediction Algorithm for Hospitalized COVID-19 Patients
1 other identifier
observational
600
1 country
7
Brief Summary
Severe acute respiratory syndrome coronavirus 2-mediated coronavirus disease (COVID-19) is an evolutionarily unprecedented natural experiment that causes major changes to the host immune system. We propose to develop a test that accurately predicts short- and long-term (within one-year) outcomes in hospitalized COVID-19 patients broadly reflecting US demographics who are at increased risk of adverse outcomes from COVID-19 using both clinical and molecular data. We will enroll patients from a hospitalized civilian population in one of the country's largest metropolitan areas and a representative National Veteran's population.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2022
Typical duration for all trials
7 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 15, 2022
CompletedFirst Posted
Study publicly available on registry
July 22, 2022
CompletedStudy Start
First participant enrolled
August 8, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
May 31, 2026
ExpectedApril 24, 2026
April 1, 2026
3.7 years
July 15, 2022
April 22, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
New onset or worsening frailty, single organ dysfunction, multi-organ dysfunction, and death within one year
The primary outcome clinical composite endpoints that include new onset or worsening frailty, single organ dysfunction, multi organ dysfunction, and death within one year will include a follow-up period of time of at least 52 weeks after initial enrollment encounter. The assessment of time to event (outcome events will include various frailty measurement tools including short physical performance battery, laboratory test-based organ function assessment measures, and survival status as per publicly-accessible databases) will consist of calculating the time difference between first outcome event and baseline encounter date.
From hospital admission to one year
Secondary Outcomes (1)
New onset or worsening frailty, single organ dysfunction, multi-organ dysfunction, and death at time of discharge
From hospital admission to time of discharge
Study Arms (2)
civilian
Veteran
Interventions
Eligibility Criteria
Symptomatic COVID-19 infected civilians and symptomatic COVID-19 infected veterans
You may qualify if:
- Symptomatic COVID-19 infection with hospital admission
- Age 18 and above
- Informed consent
You may not qualify if:
- Absence of symptomatic COVID-19 infection with hospital admission
- Age 17 or below
- No informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of California, Los Angeleslead
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Centercollaborator
- Olive View-UCLA Education & Research Institutecollaborator
- VA Greater Los Angeles Healthcare Systemcollaborator
- Michael E. DeBakey VA Medical Centercollaborator
- Atlanta VA Medical Centercollaborator
- Bronx VA Medical Centercollaborator
Study Sites (7)
VA Greater Los Angeles Healthcare System
Los Angeles, California, 90073, United States
Ronald Reagan UCLA Medical Center
Los Angeles, California, 90095, United States
Olive View-UCLA Education & Research Institute
Sylmar, California, 91342, United States
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California, 90502, United States
Atlanta VA Medical Center
Decatur, Georgia, 30033, United States
Bronx VA Medical Center
The Bronx, New York, 10468, United States
Michael E. DeBakey VA Medical Center
Houston, Texas, 77030, United States
Related Publications (1)
Deng MC. Multi-dimensional COVID-19 short- and long-term outcome prediction algorithm. Expert Rev Precis Med Drug Dev. 2020;5(4):239-242. doi: 10.1080/23808993.2020.1785286. Epub 2020 Jun 24. No abstract available.
PMID: 33283045BACKGROUND
Biospecimen
Peripheral blood and nasal swab
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor of Medicine
Study Record Dates
First Submitted
July 15, 2022
First Posted
July 22, 2022
Study Start
August 8, 2022
Primary Completion
April 30, 2026
Study Completion (Estimated)
May 31, 2026
Last Updated
April 24, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
- Time Frame
- The data will be available following the completion of the study and will be available indefinitely.
- Access Criteria
- COPA Study website to be determined
After our data is cleaned, quality checked, and analyzed, we will make the data available to the general research community. Data collected in this proposal will be submitted to the appropriate public databases (e.g. Gene Expression Omnibus), along with complete documentation to enable efficient use of the data by the general research community. Cumulative datasets will be submitted on a regular basis in a timely manner. All data made available for public use will be de-identified data, i.e., stripped of private, protected health information that could be used to deduce the identity of individual subjects, in compliance with the HIPPA Privacy Rule. The study will be registered in the database of Genotypes and Phenotypes and the following data and information will be shared through the Sequence Read Archive and Gene Expression Omnibus.